An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes

PharmacoEconomics

Volumn 26, Issue 4, 2008, Pages 329-339

  Ramsey, Scott D ^a,b   Clarke, Lauren D ^c   Roberts, Craig S ^d   Sullivan, Sean D ^a,b   Johnson, Scott J ^e   Liu, Larry Z ^d  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Cornerstone NW ^*  (United States)

^d PFIZER INC   (United States)

^e ANALYSIS GROUP   (United States)

Author keywords

Atorvastatin, therapeutic use; Cardiovascular disorders, treatment; Cost effectiveness; Cost utility; HMG CoA reductase inhibitors, therapeutic use; Myocardial infarction, treatment; Stroke, treatment

Indexed keywords

ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC ASPECT; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURVIVAL; UNITED STATES;

CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MODELS, ECONOMIC; PYRROLES; QUALITY-ADJUSTED LIFE YEARS;

EID: 41449093926     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200826040-00005     Document Type: Article

References (18)

1. American Diabetes Association. Standards of medical care in diabetes: 2006. Diabetes Care 2006; 29 Suppl. 1: S4-42
2. Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008 Jan 12; 371 (9607): 117-25
3. Colhoun HM, Betteridge DJ, Durrington PN, et al., on behalf of the CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): a multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-96
4. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998 Jul 23; 339 (4): 229-34
5. Huang ES, Shook M, Jin L, et al. The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetes. Diabetes Care 2006 Feb; 29 (2): 259-64
6. Maddigan SL, Feeny DH, Majumdar SR, et al. Understanding the determinants of health for people with type 2 diabetes. Am J Public Health 2006 Sep; 96 (9): 1649-55
7. O'Brien JA, Shomphe LA, Kavanagh PL, et al. Direct medical costs of complications resulting from type 2 diabetes in the US. Diabetes Care 1998 Jul; 21 (7): 1122-8
8. Consumer price index: all urban consumers. Base period: 1984-2; item: medical care; area: US city average; not seasonally adjusted [series ID: CUUR0000SAM]. US Bureau of Labor Statistics [online]. Available from URL: http://data.bls.gov/cgi-bin/srgate [Accessed 2008 Feb 14]
9. Stevens RJ, Kothari V, Adler AI, et al., United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond) 2001 Dec; 101 (6): 671-9
10. Kothari V, Stevens RJ, Adler AI, et al. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 2002 Jul; 33 (7): 1776-81
11. D'Agostino Sr RB, Grundy S, Sullivan LM, et al., CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001 Jul 11; 286 (2): 180-7
12. US Department of Health and Human Services. Centers for Disease Control and Prevention. National Center for Health Statistics. NHANES: National Health and Nutrition Examination Survey, 1999-2002 sample [online]. Available from URL: http://www.cdc.gov/nchs/nhanes.htm [Accessed 2005 Jul 5]
13. World Health Organization. Health statistics and health information systems: mortality data [online]. Available from URL: http://www.who.int/ healthinfo/statistics/mortality/en/index.html [Accessed 2006 Nov 22]
14. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996 Oct 16; 276 (15): 1253-8
15. Raikou M, McGuire A, Colhoun HM, et al., CARDS Investigators. Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 2007; 50: 733-40
16. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326: 1407-8
17. Mantel-Teeuwisse AK, Goettsch WG, Klungel OH, et al. Long term persistence with statin treatment in daily medical practice. Heart 2004; 90 (9): 1065-6
18. Pharmacy facts and figures. Drug Topics [online]. Available from URL: http://www.drugtopics.com/Pharmacy+Facts+And+Figures [Accessed 2008 Feb 1]